Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy, safety, and tolerability of BMS-986368 for agitation in participants with Alzheimer's disease. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation
• Alzheimer Disease

Drugs mentioned

• BMS-986368

Snippet

Sponsor: Celgene | Conditions: Agitation, Alzheimer Disease | Phase 2 | Status: RECRUITING